Anti-Cd19/Cd22 Car-T Cells
MRD-positive
Shanghai General Hospital, Shanghai Jiao Tong University School of MedicineCell therapyPhase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 32/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the MRD-positive cohort.
Same molecule, other indications
Anti-Cd19/Cd22 Car-T Cells is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →